Effect of Lanthanum Carbonate Treatment on Bone in Japanese Dialysis Patients With Hyperphosphatemia

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 2, 2011, Pages 176-184

  Shigematsu, Takashi ^a   Tokumoto, Akihide ^b   Nakaoka, Akihisa ^c   Arisaka, Hiroaki ^d  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^b Kamifukubara Clinic   (Japan)

^c SAN IN ROSAI HOSPITAL   (Japan)

^d IBARAKI PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Bone biopsy; Hyperphosphatemia; Lanthanum carbonate; Phosphate binder; Renal osteodystrophy

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; CALCIUM; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR ACTIVATOR;

ADULT; ADYNAMIC BONE DISEASE; AGED; ARTICLE; BONE BIOPSY; BONE DISEASE; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DRUG BONE LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG FATALITY; DRUG WITHDRAWAL; FEMALE; HEART VENTRICLE EXTRASYSTOLE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; HYPERPHOSPHATEMIA; JAPANESE; MALE; MORPHOMETRICS; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OSTEITIS FIBROSA; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL OSTEODYSTROPHY; STOMACH DISCOMFORT; VOMITING;

ADULT; AGED; BONE AND BONES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; PHOSPHORUS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY; YOUNG ADULT;

EID: 79953033976     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00898.x     Document Type: Article

References (25)

1. Delmez JA, Slatopolsky E. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease. Am J Kidney Dis 1992;19:303-17.
2. Moe S, Drueke T, Cunningham J etal. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney disease: improving global outcomes (KDIGO). Kidney Int 2006;69:1945-53.
3. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995;333: 166-74.
4. Sherrard DJ, Hercz G, Pei Y etal. The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 1993;43:436-42.
5. Hsu CH. Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-9.
6. Savica V, Calo LA, Monardo P, Santoro D, Bellinghieri G. Phosphate binders and management of hyperphosphataemia in end-stage renal disease. Nephrol Dial Transplant 2006;21:2065-8.
7. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant 2004;19(Suppl 1):i9-13.
8. Monier-Faugere MC, Malluche HH. Trends in renal osteodystrophy: a survey from 1983 to 1995 in a total of 2248 patients. Nephrol Dial Transplant 1996;11(Suppl 3):111-20.
9. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6years of treatment. Nephron Clin Pract 2008;110:c15-23.
10. Hutchison AJ, Maes B, Vanwalleghem J etal. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006;102:c61-71.
11. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003;42:96-107.
12. Shigematsu T. Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 2008;12:55-61.
13. Albaaj F, Hutchison AJ. Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients. Int J Clin Pract 2005;59:1091-6.
14. Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 2004;13:403-9.
15. D'Haese PC, Spasovski GB, Sikole A etal. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003;85:S73-8.
16. Malluche HH, Siami GA, Swanepoel C etal. Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years. Clin Nephrol 2008;70:284-95.
17. Freemont AJ, Hoyland JA, Denton J. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease. Clin Nephrol 2005;64:428-37.
18. Malluche HH, Mawad H, Monier-Faugere MC. Effects of treatment of renal osteodystrophy on bone histology. Clin J Am Soc Nephrol 2008;3(Suppl 3):S157-63.
19. Damment SJ, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47:553-63.
20. Spasovski GB, Sikole A, Gelev S etal. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1year of treatment with lanthanum carbonate and after 2years of follow-up. Nephrol Dial Transplant 2006;21:2217-24.
21. Behets GJ, Verberckmoes SC, Oste L etal. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005;67:1830-6.
22. Barton Pai A, Conner TA, McQuade CR. Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opin Drug Metab Toxicol 2009;5:71-81.
23. Behets GJ, Dams G, Vercauteren SR etal. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004;15:2219-28.
24. Damment SJ, Shen V. Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats. Clin Nephrol 2005;63:127-37.
25. Bronner F, Slepchenko BM, Pennick M, Damment SJ. A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate. Clin Pharmacokinet 2008;47:543-52.